LONDON (dpa-AFX) - Oxford BioMedica plc (OXB.L) said its partners at Cardiff University, Wales (UK) have begun a Phase II study to evaluate the safety and immunological activity of TroVax, a therapeutic vaccine developed by Oxford BioMedica, in patients with inoperable metastatic colorectal cancer or CRC. The study would be funded by Cardiff University, with some funding awarded by Cancer Research Wales, and Oxford BioMedica would provide TroVax.
The randomised, open-label Phase II study, entitled 'TaCTiCC' or TroVax and Cyclophosphamide Treatment in Colorectal Cancer, builds on four previous Phase I/II trials conducted by Oxford BioMedica where TroVax was given to patients with CRC, further to research into CRC undertaken by Andrew Godkin and Awen Gallimore at Cardiff University, Wales. The study, led by Andrew Godkin, would enrol up to 54 patients with inoperable metastatic CRC.
The trial would assess whether TroVax, administered alone or in combination with cyclophosphamide, is effective in treating CRC. Also, the study would evaluate anti-5T4 immune responses following treatment, in addition to secondary measures of clinical benefit including progression-free survival, objective response rate and overall survival.
TroVax is a therapeutic vaccine, which stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen which is present on most solid tumours.
Copyright RTT News/dpa-AFX
© 2012 AFX News
